CO6251236A2 - Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico - Google Patents
Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilicoInfo
- Publication number
- CO6251236A2 CO6251236A2 CO09146050A CO09146050A CO6251236A2 CO 6251236 A2 CO6251236 A2 CO 6251236A2 CO 09146050 A CO09146050 A CO 09146050A CO 09146050 A CO09146050 A CO 09146050A CO 6251236 A2 CO6251236 A2 CO 6251236A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- composition
- dihydroquinolin
- oxo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 239000002253 acid Substances 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 3-chloro-2-fluorobenzyl Chemical group 0.000 abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 2
- 229960004525 lopinavir Drugs 0.000 abstract 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 2
- 229960000311 ritonavir Drugs 0.000 abstract 2
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 abstract 1
- 102000018832 Cytochromes Human genes 0.000 abstract 1
- 108010052832 Cytochromes Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94732507P | 2007-06-29 | 2007-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6251236A2 true CO6251236A2 (es) | 2011-02-21 |
Family
ID=39817166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09146050A CO6251236A2 (es) | 2007-06-29 | 2009-12-21 | Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20110009411A1 (enExample) |
| EP (1) | EP2167089A1 (enExample) |
| JP (3) | JP5547067B2 (enExample) |
| KR (1) | KR20100028656A (enExample) |
| CN (2) | CN101743004A (enExample) |
| AP (1) | AP2490A (enExample) |
| AR (1) | AR067184A1 (enExample) |
| AU (1) | AU2008270634B2 (enExample) |
| BR (1) | BRPI0813955A2 (enExample) |
| CA (1) | CA2691736A1 (enExample) |
| CO (1) | CO6251236A2 (enExample) |
| EA (1) | EA200971096A1 (enExample) |
| EC (1) | ECSP109889A (enExample) |
| IL (1) | IL202745A0 (enExample) |
| MX (1) | MX2009013828A (enExample) |
| NZ (1) | NZ582089A (enExample) |
| SG (1) | SG182228A1 (enExample) |
| TW (1) | TW200916103A (enExample) |
| UA (1) | UA103881C2 (enExample) |
| WO (1) | WO2009006203A1 (enExample) |
| ZA (1) | ZA201000468B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976517A1 (en) * | 2005-12-30 | 2008-10-08 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008033836A2 (en) | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| EP2555757B1 (en) * | 2010-04-09 | 2016-05-25 | Bristol-Myers Squibb Holdings Ireland | Atazanavir sulfate formulations with improved ph effect |
| US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| HK1204980A1 (en) * | 2012-03-01 | 2015-12-11 | Gilead Sciences, Inc. | Spray dried formulations |
| AU2013296289B2 (en) | 2012-08-03 | 2017-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| SK2662004A3 (sk) * | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| WO2005034001A1 (en) * | 2003-10-09 | 2005-04-14 | Steven Wheeler | Adaptive medical decision support system |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP1758581A1 (en) * | 2004-05-21 | 2007-03-07 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP1976517A1 (en) * | 2005-12-30 | 2008-10-08 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| PL2049506T5 (pl) * | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008033836A2 (en) * | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 AR ARP080102760A patent/AR067184A1/es not_active Application Discontinuation
- 2008-06-26 TW TW097123981A patent/TW200916103A/zh unknown
- 2008-06-26 NZ NZ582089A patent/NZ582089A/xx not_active IP Right Cessation
- 2008-06-26 JP JP2010515115A patent/JP5547067B2/ja not_active Expired - Fee Related
- 2008-06-26 CA CA002691736A patent/CA2691736A1/en not_active Abandoned
- 2008-06-26 AU AU2008270634A patent/AU2008270634B2/en not_active Ceased
- 2008-06-26 UA UAA200913904A patent/UA103881C2/ru unknown
- 2008-06-26 EA EA200971096A patent/EA200971096A1/ru unknown
- 2008-06-26 KR KR1020107001984A patent/KR20100028656A/ko not_active Ceased
- 2008-06-26 BR BRPI0813955A patent/BRPI0813955A2/pt not_active IP Right Cessation
- 2008-06-26 CN CN200880022821A patent/CN101743004A/zh active Pending
- 2008-06-26 SG SG2012046926A patent/SG182228A1/en unknown
- 2008-06-26 AP AP2009005083A patent/AP2490A/xx active
- 2008-06-26 WO PCT/US2008/068351 patent/WO2009006203A1/en not_active Ceased
- 2008-06-26 US US12/666,995 patent/US20110009411A1/en not_active Abandoned
- 2008-06-26 EP EP20080781024 patent/EP2167089A1/en not_active Withdrawn
- 2008-06-26 MX MX2009013828A patent/MX2009013828A/es not_active Application Discontinuation
- 2008-06-26 CN CN2013101948825A patent/CN103356622A/zh active Pending
- 2008-06-26 US US12/147,220 patent/US20090093482A1/en not_active Abandoned
-
2009
- 2009-12-15 IL IL202745A patent/IL202745A0/en unknown
- 2009-12-21 CO CO09146050A patent/CO6251236A2/es not_active Application Discontinuation
-
2010
- 2010-01-21 ZA ZA2010/00468A patent/ZA201000468B/en unknown
- 2010-01-21 EC EC2010009889A patent/ECSP109889A/es unknown
-
2013
- 2013-07-08 JP JP2013142320A patent/JP5769762B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,790 patent/US20140343062A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094705A patent/JP2015143277A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,070 patent/US20170136000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201000468B (en) | 2011-06-29 |
| EA200971096A1 (ru) | 2010-08-30 |
| US20170136000A1 (en) | 2017-05-18 |
| ECSP109889A (es) | 2010-03-31 |
| IL202745A0 (en) | 2010-06-30 |
| AP2009005083A0 (en) | 2009-12-31 |
| AR067184A1 (es) | 2009-09-30 |
| CN101743004A (zh) | 2010-06-16 |
| JP2010532373A (ja) | 2010-10-07 |
| AU2008270634A1 (en) | 2009-01-08 |
| US20090093482A1 (en) | 2009-04-09 |
| BRPI0813955A2 (pt) | 2017-05-09 |
| MX2009013828A (es) | 2010-03-10 |
| KR20100028656A (ko) | 2010-03-12 |
| WO2009006203A1 (en) | 2009-01-08 |
| JP2015143277A (ja) | 2015-08-06 |
| SG182228A1 (en) | 2012-07-30 |
| UA103881C2 (ru) | 2013-12-10 |
| JP2013199494A (ja) | 2013-10-03 |
| EP2167089A1 (en) | 2010-03-31 |
| TW200916103A (en) | 2009-04-16 |
| NZ582089A (en) | 2013-01-25 |
| US20110009411A1 (en) | 2011-01-13 |
| CA2691736A1 (en) | 2009-01-08 |
| US20140343062A1 (en) | 2014-11-20 |
| AP2490A (en) | 2012-10-04 |
| AU2008270634B2 (en) | 2014-01-16 |
| JP5769762B2 (ja) | 2015-08-26 |
| JP5547067B2 (ja) | 2014-07-09 |
| CN103356622A (zh) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251236A2 (es) | Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| CL2010001358A1 (es) | Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2007002234A1 (es) | Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas. | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2009001980A1 (es) | Combinacion farmaceutica que comprende un derivado de quinolina y uno o mas de otros agentes antimicobacterianos; composicion farmaceutica que la comprende; y uso para el tratamiento de una infeccion por una cepa de mycobacterium resistente a farmacos (divisional de la solicitud 1290-05). | |
| AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| BR112012033077B8 (pt) | Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit | |
| ECSP109897A (es) | Composiciones terapeuticas y usos de las mismas | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| ECSP15051434A (es) | Composición farmacéutica de dosis baja | |
| PY1737795A (es) | Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible | |
| AR059357A1 (es) | Formulaciones farmaceuticas | |
| CO6321158A2 (es) | Formulacion oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |